Clinical Trial Data Release


14:00 - 17:00
  • 临床数据全球首发专场
  • Clinical Trial Data Release
14:00 - 15:20
  • 第一阶段
  • Phase I
  • Moderator
  • 杨大俊 , 亚盛医药董事长兼CEO
  • YANG Dajun , Chairman & CEO of Ascentage Pharma
14:00 - 14:20
  • 加科思药业集团有限公司
  • Jacobio Pharmaceuticals Group Co., Ltd.
  • 项目1:加科思KRAS G12C抑制剂JAB-21822单药或者联合治疗晚期实体瘤I /II期临床数据
  • Project 1: Jacobio Phase I/II Clinical Data of KRAS G12C Inhibitor Glecirasib (JAB-21822) Monotherapy and Combination Treatment for Advanced Solid Tumors
  • 石远凯 中国医学科学院北京协和医学院长聘教授、中国癌症基金会理事长
  • SHI Yuankai , Professor in Tenure, Chinese Academy of Medical Sciences & Peking Union Medical College; Chairman of Cancer Foundation of China
14:20 - 14:40
  • 中天(上海)生物科技有限公司
  • Microbio (Shanghai) Co., Ltd.
  • 项目2:全球首创广效抗新冠药物MBS-COV(SNS812)简介及一期临床结果首发
  • Project 2: Introduction to the World's First Broad-Spectrum Anti-SARS-CoV-2 Drug, MBS-COV(SNS812), and the First Release of Phase I Clinical Trial Results
  • 張翼中 中天(上海)生物科技有限公司总经理
  • Owen Chang , General Manager, Microbio (Shanghai) Co., Ltd.
14:40 - 15:00
  • 深圳市真兴医药技术有限公司
  • Shenzhen Zhenxing Medical Technology Co., Ltd.
  • 项目3:富马酸奥比特嗪肠溶微丸胶囊(SM-1)和替莫唑胺联用治疗复发高级别脑胶质瘤I期临床研究:初步结果
  • Project 3:Phase I Clinical Study of SM-1 in Combination with Temozolomide for Recurrent High-Grade Gliomas: Preliminary Results
  • 李文斌 首都医科大学附属北京天坛医院肿瘤综合治疗中心主任
  • LI Wenbin , Director of Cancer Center, Beijing Tiantan Hospital, Capital Medical University
15:00 - 15:20
  • 丹诺医药(苏州)有限公司
  • TenNor Therapeutics (Suzhou) Limited
  • 项目4:TNP-2198治疗幽门螺杆菌感染I/II期临床试验结果
  • Project 4: Results of Phase I/II Clinical Trials of TNP-2198 for the Treatment of Helicobacter Pylori Infection
  • 丁艳华 吉林大学第一医院 I期药物临床试验病房主任
  • DING Yanhua , Director, Phase I Clinical Center, Jilin University First Hospital
15:20 - 17:00
  • 第二阶段
  • Phase II
  • Moderator
  • 陈力 , 华领医药创始人、董事长、首席执行官
  • CHEN Li , Founder, Executive Director, CEO of Hua Medicine
15:20 - 15:40
  • 上海银诺医药技术有限公司
  • Shanghai Innogen Pharmaceutical Technology Co., Ltd.
  • 项目5:苏帕鲁肽注射液的药效学及安全性临床数据汇报
  • Project 5: Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Supaglutide, a Novel Weekly Dosing GLP-1 Based Therapy
  • 吴海娅 上海银诺医药技术有限公司助理副总裁、医学部负责人
  • WU Haiya , Assistant Vice President, Head of Medical Division, Shanghai Innogen Pharmaceutical Technology Co., Ltd.
15:40 - 16:00
  • 朗捷睿(苏州)生物科技有限公司
  • Longivitron(SuZhou) Biotechnology Co., Ltd.
  • 项目6:高选择性S1P1受体激动剂LJR001治疗类风湿关节炎(RA)I/IIa期临床试验
  • Project 6: Phase I/IIa Clinical Trial of LJR001, A Highly Selective S1P1 Receptor Agonist for Rheumatoid Arthritis (RA)
  • 丁艳华 吉林大学第一医院 I期药物临床试验病房主任
  • DING Yanhua , Director, Phase I Clinical Center, Jilin University First Hospital
16:00 - 16:20
  • 合一生技股份有限公司
  • Oneness Biotech Co., Ltd.
  • 项目7:我国第一件糖尿病足溃疡新药,上市后案例研究
  • Project 7: The First New Drug in Treating Diabetic Foot Ulcers in China - Real-World Cases Report
  • 张舜程 双和医院整形外科主任,台湾外科医学会常务监事,台湾伤口照护学会理事,台北医学大学外科系助理教授
  • Shun-Cheng Chang , Director, Division of Plastic Surgery, Department of Surgery, Taipei Medical University-Shuang Ho Hospital, Taiwan; Executive Supervisor, Taiwan Surgical Association; Director, Taiwan Society For Wound Care; Assistant professor, Department of Surgery, Taipei Medical University
16:20 - 16:40
  • 广州再极医药科技有限公司
  • Guangzhou Maxinovel Pharmaceuticals Co., Ltd.
  • 项目8:MAX-40279:FLT3野生型AML治疗的新突破
  • Project 8: MAX-40279 as the Novel Treatment of FLT3 Wildtype Acute Myeloid Leukemia
  • 冯振华 再极医药科技有限公司科学与运营副总裁
  • FENG Zhenhua , Vice President of Science and Operations, Maxinovel Pharma.
16:40 - 17:00
  • 明济生物制药(北京)有限公司
  • FutureGen Biopharmaceutical(Beijing) Co., Ltd.
  • 项目9:靶向CLDN18.2 ADCC增强型单抗FG-M108应用于晚期胃癌的临床Ⅰ/Ⅱ期试验
  • Project 9:The Phase Ⅰ/Ⅱ Clinical Study of Monoclonal Antibody FG-M108 Targeting CLDN18.2 with Enhanced ADCC Activity for Advanced Gastric Cancer
  • 靳照宇 明济生物制药(北京)有限公司董事长&CEO
  • JIN Zhaoyu , Chaiman&CEO of FutureGen Biopharmaceutical (Beijing) Co., Ltd.